Tempus AI Launches Digital Pathology Open-Source Consortium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
- Consortium Formation: Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center have launched the digital pathology IMS Open-Source Consortium, aimed at accelerating the democratization and standardization of digital pathology to promote widespread clinical adoption.
- Technology Sharing: Tempus will open source its existing Paige Image Management System, including the slide viewer and case management solutions, thereby providing clinical-grade digital pathology baseline solutions to institutions globally, enhancing the application potential of pathology.
- Industry Collaboration: As founding members, YNHH and MSK will collaboratively define the vision and strategic direction of the open-source ecosystem, fostering cooperation between academia and industry partners to drive an open, scalable, and interoperable digital pathology environment.
- Growing Market Demand: With rising demand for diagnostic and biomarker testing, digital pathology presents a unique opportunity to optimize tissue utilization and improve laboratory workflows, and Tempus looks forward to enhancing patient care quality through this consortium.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 54.870
Low
76.00
Averages
84.38
High
105.00
Current: 54.870
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SoundThinking and SELLAS Options Trading Activity
- SoundThinking Options Activity: SoundThinking Inc (Symbol: SSTI) has seen an options trading volume of 800 contracts today, representing approximately 80,000 shares, which accounts for 62.1% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within SSTI, the $7.50 strike put option has been particularly active, with 799 contracts traded today, representing about 79,900 shares, reflecting investor expectations regarding potential downside risks for the stock.
- SELLAS Options Activity: SELLAS Life Sciences Group Inc (Symbol: SLS) has recorded an options trading volume of 50,636 contracts today, equating to approximately 5.1 million shares, or 61.3% of its average daily trading volume over the past month, showcasing strong market interest in its stock.
- High Volume Call Options: For SLS, the $15 strike call option has seen a trading volume of 3,278 contracts today, representing around 327,800 shares, indicating investor confidence in the stock's potential for future gains.
See More
Tempus AI Partners with Angiosarcoma Awareness to Advance Research
- Research Collaboration Initiated: Tempus AI has partnered with Angiosarcoma Awareness, Inc. to leverage approximately 600 de-identified angiosarcoma records, aiming to accelerate research on this rare cancer, which is expected to significantly enhance understanding of angiosarcoma biology and advance precision medicine.
- Data Resource Integration: This collaboration will integrate Tempus' multimodal molecular and clinical data to help researchers identify biological patterns and potential therapeutic opportunities, thereby overcoming challenges in rare cancer research related to data fragmentation and lack of effective pre-clinical models.
- Enhanced Patient Engagement: The collaboration builds on the Angiosarcoma Project launched in 2017, aiming to directly involve patients and families in angiosarcoma research, enhancing patient voices and participation in scientific discovery.
- Commitment to Precision Medicine: Tempus' Chief Medical Officer, Ezra Cohen, emphasized that precision medicine should not be limited by data availability, and this collaboration will provide better treatment options for rare cancer patients, reflecting the company's strong commitment to advancing precision medicine.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
Tempus AI Receives FDA Clearance for Atrial Fibrillation Prediction Software
- FDA Approval: Tempus AI's ECG software received FDA clearance in 2024 for predicting the risk of atrial fibrillation (AF) in patients aged 65 and older, marking a significant advancement in the field of precision medicine.
- Multi-Center Validation Study: The study evaluated 4,017 patients across three distinct clinical sites, demonstrating that the ECG-AI risk score exceeded pre-specified performance thresholds, indicating the technology's reliability in diverse clinical environments and potentially transforming early risk detection in cardiac care.
- Clinical Application Potential: Findings suggest that the Tempus ECG-AF software can assist clinicians in identifying hidden AF risks earlier, thereby helping to minimize serious complications such as stroke and heart failure, ultimately enhancing overall patient care quality.
- Technological Innovation: The Tempus ECG-AF is the first FDA-cleared ECG-AI device designed to analyze 12-lead ECG recordings to detect early signs of AF, further advancing the company's technological development in the cardiovascular disease sector.
See More
ExomeReveal RNA Analysis Enhances Genetic Diagnosis Clarity
- Significant Research Findings: Ambry Genetics' study demonstrates that RNA analysis through the ExomeReveal workflow can provide clearer diagnoses for nearly 2,000 genetic variants, particularly as about 10% of these variants were suspected to affect gene splicing, highlighting the necessity and efficacy of RNA testing.
- Resolving Uncertain Variants: Among patients participating in follow-up RNA testing, approximately 8% of variants qualified for further RNA analysis, with more than one-third originally classified as Variants of Uncertain Significance, indicating the critical role of RNA testing in clinical applications.
- Clinical Decision Support: The study emphasizes that combining RNA with exome sequencing offers visibility into molecular-level information, aiding physicians in making more precise clinical decisions, thus meeting the needs of patients and their families for clear answers and enhancing patient care quality.
- Future Application Prospects: The proposed criteria for RNA testing provide guidance for widespread adoption across clinical laboratories, indicating that integrating RNA testing into diagnostic pipelines is achievable and impactful, potentially transforming the diagnosis of genetic diseases.
See More
Tempus AI Expands Beyond Diagnostics with Healthcare Data Platform
- Business Expansion Strategy: Tempus AI is striving to move beyond traditional diagnostics by building a growing healthcare data platform integrated with AI tools, aiming for sustainable profit growth that enhances its market competitiveness.
- FDA Progress: The company's advancements with the FDA provide crucial support for market access of its products, and successful navigation of this process could significantly boost investor confidence and drive stock price appreciation.
- Pharma Partnerships: Tempus AI's deepening partnerships with pharmaceutical companies not only facilitate the application of its technologies but also have the potential to generate new revenue streams, further driving business diversification.
- Market Expectation Challenges: Despite the promising outlook, the current stock price reflects high market expectations, making execution capability a key focus for investors, which will ultimately determine future stock price movements.
See More
SoundThinking and SELLAS Options Trading Activity
- SoundThinking Options Activity: SoundThinking Inc (Symbol: SSTI) has seen an options trading volume of 800 contracts today, representing approximately 80,000 shares, which accounts for 62.1% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within SSTI, the $7.50 strike put option has been particularly active, with 799 contracts traded today, representing about 79,900 shares, reflecting investor expectations regarding potential downside risks for the stock.
- SELLAS Options Activity: SELLAS Life Sciences Group Inc (Symbol: SLS) has recorded an options trading volume of 50,636 contracts today, equating to approximately 5.1 million shares, or 61.3% of its average daily trading volume over the past month, showcasing strong market interest in its stock.
- High Volume Call Options: For SLS, the $15 strike call option has seen a trading volume of 3,278 contracts today, representing around 327,800 shares, indicating investor confidence in the stock's potential for future gains.
See More
Tempus AI Partners with Angiosarcoma Awareness to Advance Research
- Research Collaboration Initiated: Tempus AI has partnered with Angiosarcoma Awareness, Inc. to leverage approximately 600 de-identified angiosarcoma records, aiming to accelerate research on this rare cancer, which is expected to significantly enhance understanding of angiosarcoma biology and advance precision medicine.
- Data Resource Integration: This collaboration will integrate Tempus' multimodal molecular and clinical data to help researchers identify biological patterns and potential therapeutic opportunities, thereby overcoming challenges in rare cancer research related to data fragmentation and lack of effective pre-clinical models.
- Enhanced Patient Engagement: The collaboration builds on the Angiosarcoma Project launched in 2017, aiming to directly involve patients and families in angiosarcoma research, enhancing patient voices and participation in scientific discovery.
- Commitment to Precision Medicine: Tempus' Chief Medical Officer, Ezra Cohen, emphasized that precision medicine should not be limited by data availability, and this collaboration will provide better treatment options for rare cancer patients, reflecting the company's strong commitment to advancing precision medicine.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
Tempus AI Receives FDA Clearance for Atrial Fibrillation Prediction Software
- FDA Approval: Tempus AI's ECG software received FDA clearance in 2024 for predicting the risk of atrial fibrillation (AF) in patients aged 65 and older, marking a significant advancement in the field of precision medicine.
- Multi-Center Validation Study: The study evaluated 4,017 patients across three distinct clinical sites, demonstrating that the ECG-AI risk score exceeded pre-specified performance thresholds, indicating the technology's reliability in diverse clinical environments and potentially transforming early risk detection in cardiac care.
- Clinical Application Potential: Findings suggest that the Tempus ECG-AF software can assist clinicians in identifying hidden AF risks earlier, thereby helping to minimize serious complications such as stroke and heart failure, ultimately enhancing overall patient care quality.
- Technological Innovation: The Tempus ECG-AF is the first FDA-cleared ECG-AI device designed to analyze 12-lead ECG recordings to detect early signs of AF, further advancing the company's technological development in the cardiovascular disease sector.
See More
ExomeReveal RNA Analysis Enhances Genetic Diagnosis Clarity
- Significant Research Findings: Ambry Genetics' study demonstrates that RNA analysis through the ExomeReveal workflow can provide clearer diagnoses for nearly 2,000 genetic variants, particularly as about 10% of these variants were suspected to affect gene splicing, highlighting the necessity and efficacy of RNA testing.
- Resolving Uncertain Variants: Among patients participating in follow-up RNA testing, approximately 8% of variants qualified for further RNA analysis, with more than one-third originally classified as Variants of Uncertain Significance, indicating the critical role of RNA testing in clinical applications.
- Clinical Decision Support: The study emphasizes that combining RNA with exome sequencing offers visibility into molecular-level information, aiding physicians in making more precise clinical decisions, thus meeting the needs of patients and their families for clear answers and enhancing patient care quality.
- Future Application Prospects: The proposed criteria for RNA testing provide guidance for widespread adoption across clinical laboratories, indicating that integrating RNA testing into diagnostic pipelines is achievable and impactful, potentially transforming the diagnosis of genetic diseases.
See More
Tempus AI Expands Beyond Diagnostics with Healthcare Data Platform
- Business Expansion Strategy: Tempus AI is striving to move beyond traditional diagnostics by building a growing healthcare data platform integrated with AI tools, aiming for sustainable profit growth that enhances its market competitiveness.
- FDA Progress: The company's advancements with the FDA provide crucial support for market access of its products, and successful navigation of this process could significantly boost investor confidence and drive stock price appreciation.
- Pharma Partnerships: Tempus AI's deepening partnerships with pharmaceutical companies not only facilitate the application of its technologies but also have the potential to generate new revenue streams, further driving business diversification.
- Market Expectation Challenges: Despite the promising outlook, the current stock price reflects high market expectations, making execution capability a key focus for investors, which will ultimately determine future stock price movements.
See More
